132 related articles for article (PubMed ID: 21983597)
1. Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans.
Yi HA; Panepinto JC; Jacobs A
Microb Pathog; 2012 Jan; 52(1):25-30. PubMed ID: 21983597
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae.
Pettoello-Mantovani M; Casadevall A; Smarnworawong P; Goldstein H
AIDS Res Hum Retroviruses; 1994 Sep; 10(9):1079-87. PubMed ID: 7826695
[TBL] [Abstract][Full Text] [Related]
3. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
4. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
Yauch LE; Lam JS; Levitz SM
PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
[TBL] [Abstract][Full Text] [Related]
5. Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.
Rodrigues ML; Nimrichter L; Oliveira DL; Frases S; Miranda K; Zaragoza O; Alvarez M; Nakouzi A; Feldmesser M; Casadevall A
Eukaryot Cell; 2007 Jan; 6(1):48-59. PubMed ID: 17114598
[TBL] [Abstract][Full Text] [Related]
6. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
[TBL] [Abstract][Full Text] [Related]
7. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection.
Abadi J; Pirofski La
J Infect Dis; 1999 Sep; 180(3):915-9. PubMed ID: 10438394
[TBL] [Abstract][Full Text] [Related]
8. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
[TBL] [Abstract][Full Text] [Related]
9. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy.
da Silva TA; Hauser PJ; Bandey I; Laskowski T; Wang Q; Najjar AM; Kumaresan PR
Cytotherapy; 2021 Feb; 23(2):119-130. PubMed ID: 33303326
[TBL] [Abstract][Full Text] [Related]
10. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
[TBL] [Abstract][Full Text] [Related]
11. Polysaccharide diversity in VNI isolates of Cryptococcus neoformans from Roraima, Northern Brazil.
Dal Pupo HD; Sena BAG; Reis FCG; Machado L; Fortes ST; de Almeida Junior JN; Godinho RMC; Rodrigues ML
Fungal Biol; 2019 Oct; 123(10):699-708. PubMed ID: 31542188
[TBL] [Abstract][Full Text] [Related]
12. Regulated Release of Cryptococcal Polysaccharide Drives Virulence and Suppresses Immune Cell Infiltration into the Central Nervous System.
Denham ST; Verma S; Reynolds RC; Worne CL; Daugherty JM; Lane TE; Brown JCS
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203547
[No Abstract] [Full Text] [Related]
13. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8.
Pericolini E; Cenci E; Monari C; De Jesus M; Bistoni F; Casadevall A; Vecchiarelli A
Cell Microbiol; 2006 Feb; 8(2):267-75. PubMed ID: 16441437
[TBL] [Abstract][Full Text] [Related]
14. Glucuronoxylomannan intranasal challenge prior to Cryptococcus neoformans pulmonary infection enhances cerebral cryptococcosis in rodents.
Lee HH; Carmichael DJ; Ríbeiro V; Parisi DN; Munzen ME; Charles-Niño CL; Hamed MF; Kaur E; Mishra A; Patel J; Rooklin RB; Sher A; Carrillo-Sepulveda MA; Eugenin EA; Dores MR; Martinez LR
PLoS Pathog; 2023 Apr; 19(4):e1010941. PubMed ID: 37115795
[TBL] [Abstract][Full Text] [Related]
15. Cryptococcus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway.
Chiapello LS; Baronetti JL; Garro AP; Spesso MF; Masih DT
Int Immunol; 2008 Dec; 20(12):1527-41. PubMed ID: 18927317
[TBL] [Abstract][Full Text] [Related]
16. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
Parra C; González JM; Castañeda E; Fiorentino S
Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
[TBL] [Abstract][Full Text] [Related]
17. Glucuronoxylomannan-mediated interaction of Cryptococcus neoformans with human alveolar cells results in fungal internalization and host cell damage.
Barbosa FM; Fonseca FL; Holandino C; Alviano CS; Nimrichter L; Rodrigues ML
Microbes Infect; 2006 Feb; 8(2):493-502. PubMed ID: 16293436
[TBL] [Abstract][Full Text] [Related]
18. Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.
van de Wetering JK; Coenjaerts FE; Vaandrager AB; van Golde LM; Batenburg JJ
Infect Immun; 2004 Jan; 72(1):145-53. PubMed ID: 14688091
[TBL] [Abstract][Full Text] [Related]
19. Glucuronoxylomannan exhibits potent immunosuppressive properties.
Monari C; Bistoni F; Vecchiarelli A
FEMS Yeast Res; 2006 Jun; 6(4):537-42. PubMed ID: 16696649
[TBL] [Abstract][Full Text] [Related]
20. Killing of cryptococcus neoformans by Staphylococcus aureus: the role of cryptococcal capsular polysaccharide in the fungal-bacteria interaction.
Saito F; Ikeda R
Med Mycol; 2005 Nov; 43(7):603-12. PubMed ID: 16396245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
